Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$14.09 - $19.87 $522,598 - $736,978
-37,090 Reduced 19.27%
155,429 $2.47 Million
Q2 2023

Aug 11, 2023

BUY
$3.75 - $20.05 $721,946 - $3.86 Million
192,519 New
192,519 $3.63 Million
Q2 2018

Aug 03, 2018

SELL
$9.52 - $12.15 $3.57 Million - $4.56 Million
-375,205 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$6.7 - $12.95 $2.51 Million - $4.86 Million
375,205 New
375,205 $3.95 Million
Q4 2017

Feb 12, 2018

SELL
$5.07 - $7.92 $2.99 Million - $4.68 Million
-590,708 Closed
0 $0
Q3 2017

Nov 08, 2017

BUY
$5.4 - $8.47 $3.19 Million - $5 Million
590,708
590,708 $4.52 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.